key: cord-0730627-um9lv53e
authors: Varnaitė, Renata; García, Marina; Glans, Hedvig; Maleki, Kimia T.; Sandberg, John Tyler; Tynell, Janne; Christ, Wanda; Lagerqvist, Nina; Asgeirsson, Hilmir; Ljunggren, Hans-Gustaf; Ahlén, Gustaf; Frelin, Lars; Sällberg, Matti; Blom, Kim; Klingström, Jonas; Gredmark-Russ, Sara
title: Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
date: 2020-05-29
journal: bioRxiv
DOI: 10.1101/2020.05.28.118729
sha: 5885daaa10be7a3ff6d037550a017259627d4fbb
doc_id: 730627
cord_uid: um9lv53e

COVID-19, caused by SARS-CoV-2, emerged in late 2019 and has since become a global pandemic. Pathogen-specific antibodies are typically a major predictor of protective immunity, yet B cell and antibody responses during COVID-19 are not fully understood. Here, we analyzed antibody-secreting cell (ASC) and antibody responses in twenty hospitalized COVID-19 patients. We observed a significant expansion of SARS-CoV-2 nucleocapsid protein-specific ASCs in all twenty COVID-19 patients using a multicolor FluoroSpot assay. Out of the 20 patients, 16 had developed SARS-CoV-2-neutralizing antibodies by the time of sampling. Additionally, we found that SARS-CoV-2-specific IgA, IgG and IgM antibody levels positively correlated with SARS-CoV-2-neutralizing antibody titers. This study constitutes a detailed description of B cell and antibody responses to SARS-CoV-2 in COVID-19, and provides tools to study immune responses to SARS-CoV-2 infection and vaccination.

Characterizing immune responses to severe acute respiratory syndrome coronavirus 2 41 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID- 19) , is an 42 important step towards understanding correlates of protection (Zhu et al. 2020 ). In the 43 majority of viral infections, pathogen-specific antibodies are one of the main contributors to 44 protective immunity, yet B cell and antibody responses during COVID-19 are currently not 45 fully understood. Early during acute infections, activated B cells differentiate into antibody-46 secreting cells (ASCs), including plasmablasts and plasma cells, which produce large 47 antibody levels measured towards SARS-CoV-2-infected cells using an immunofluorescence 115 assay (IFA) ( Figure 2C ). We found that 16 out of the 20 patients were positive in this assay, 116 with titers ranging from 40 to 5120 ( Figure 2C ). None of the healthy controls were positive in 117 any of the antibody assays ( Figure 2A ). Higher IgG levels were detected in patients who were 118 sampled later compared to early after the onset of symptoms, total and spike S1-specific 119 SARS-CoV-2 IgG antibody levels positively correlated with the number of days since 120 symptom onset (rs = 0.577, P = 0.01 and rs = 0.603, P = 0.005, respectively) (Supplemental 121 Figure 1B and C). Notably, 2 out of the 3 SARS-CoV-2 RT-PCR-positive patients lacked detectable levels of 142 neutralizing antibodies (Fig 2A) , which might allow for a more efficient viral spread in those 143 patients. However, our attempts to isolate live SARS-CoV-2 from patient serum on Vero E6 144 cells were unsuccessful (data not shown), suggesting absence or low levels of live SARS-145

CoV-2 in serum of COVID-19 patients. 146 147 148

According to the latest reports, COVID-19 patients generally present with decreased 150 lymphocyte numbers in peripheral blood (Wang et al. 2020; Qin et al. 2020; Zhang et al. 151 2020) . In line with this, we observed decreased absolute numbers of lymphocytes (CD45 + ) 152 and T cells (total CD3 + and CD3 + CD8 + cells) as compared to controls, but no significant 153 decrease of B cells (CD19 + ) or CD4 + T cells (Supplemental Figure 1G) . Furthermore, 154 COVID-19 patients showed significantly higher frequencies of activated CD8 + and CD4 + T 155 cells compared to the controls (Supplemental Figure 1H ). The frequencies of activated CD8 + 156 T cells positively correlated with activated CD4 + T cell frequencies in COVID-19 patients (rs 157 = 0.699, P < 0.001). Interestingly, CD8 + T cell activation level, but not CD4 + T cell 158 activation level, positively correlated with neutralizing antibody titers (rs = 0.544, P = 0.01; rs 159 = 0.271, P = 0.25) (Supplemental Figure 1O and P). Figure 1N) . In this study, we demonstrated that COVID-19 patients elicit a significant SARS-CoV-2-175 specific B cell response, indicated by the expansion of SARS-CoV-2-specific ASCs. 176

Although not all patients in this cohort had detectable levels of SARS-CoV-2-specific 177 antibodies at the time of sampling, SARS-CoV-2 N protein-specific ASCs could be detected 178 in all patients using the FluoroSpot assay. In addition, we showed a clear relationship 179

between the levels of SARS-CoV-2-specific antibodies and total SARS-CoV-2-neutralizing 180

antibodies. This suggests that standard serological assays may reflect the ability of COVID-181 19 patients to neutralize SARS-CoV-2, which may offer protection from a re-infection. 182

Additionally, tools employed in this study may be of relevance in the assessment of long-183 lasting immunity after SARS-CoV-2 infection and vaccination. 

The study was approved by the Regional Ethical Review Board in Stockholm, Sweden and 189 by the Swedish Ethical Review Authority. All COVID-19 patients and healthy controls 190 included in this study provided a written informed consent for participation. 

Absolute numbers of CD45 + , CD3 + , CD4 + , CD8 + , and CD19 + cells in peripheral blood were 212 measured using BD Trucount Tubes (BD Biosciences). 50 µL of anti-coagulated whole blood 213 were added into Trucount Tubes within 3 hours after blood extraction and stained with either test. Statistical significance for differences between COVID-19 patients and healthy controls 336 was determined by two-sided Mann-Whitney U test. P values of < 0.05 were considered 337 statistically significant. FlowJo software version 10.5.3 (Tree Star) was used to analyze all 338 flow cytometry data. FluoroSpot data was analyzed with Apex software (Mabtech). 339

We would like to thank the patients and healthy controls for participating in the study. We Positivity for IgA against S1-protein, IgG against S1-protein, IgM against N protein, total IgG antibodies against whole SARS-CoV-2, and SARS-CoV-2-neutralizing antibody titers (NT) are presented in the heatmap. Blue color indicates a positive response and the color scale is adjusted for the minimum positive assay value and the highest value recorded within the patient cohort for each assay. White boxes indicate values below positive threshold or below detection level for each assay. Red asterisks represent patients with detectable levels of SARS-CoV-2 RNA in serum. (B) IgA, IgG, and IgM antibody levels in COVID-19 patients and controls, analyzed by ELISAs. Dotted horizontal line indicates the threshold for positive result. OD, optical density. OD ratio = OD of the sample divided by OD of the calibrator. (C) Total SARS-CoV-2 IgG antibody titers determined by immunofluorescence assay. Patients with titers < 20 were assigned a value of 1. (D) SARS-CoV-2-neutralizing antibody titers determined by microneutralization assay. Patients with titers < 10 were assigned a value of 1. (E) Correlation between total SARS-CoV-2-specific IgG titers and SARS-CoV-2-neutrali ing antibody titers examined by Spearman's correlation test. r s : Spearman's rank correlation coefficient. P < 0.05 was considered statistically significant. Four COVID-19 patients with undetectable antibody levels in both assays are highlighted (5, 7, 10 and 13). Bar graphs display median and IQR. 

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-383

Rapid and massive virus-specific plasmablast responses during 385 acute dengue virus infection in humans

Viral and host factors related to the clinical outcome of COVID-19

A Novel Coronavirus from Patients with Pneumonia in China